Palonosetron + Aprepitant + Olanzapine (5 mg)

2 trials

Sponsors

University of Shizuoka, School of Pharmaceutical Sciences, Hoshi University Division of Applied Pharmaceutical

Conditions

breast cancermalignant tumor(only solid tumor)

Unknown Phase

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for cisplatin containing regimen

Active, not recruitingJPRN-UMIN000036489

University of Shizuoka, School of Pharmaceutical Sciencesmalignant tumor(only solid tumor)

Start: 2019-04-23Target: 85Updated: 2026-06-29

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer.

Active, not recruitingJPRN-UMIN000038644

Hoshi University Division of Applied Pharmaceuticalbreast cancer

Start: 2019-12-10Target: 89Updated: 2026-06-29